These findings, together with recent studies using conditional mutant mice and ALK7 blocking antibodies [5,26] support the validity of ALK7 as a therapeutic target in human obesity and its metabolic consequences. This evidence concerns the gene ACVR1C and obesity due to melanocortin 4 receptor deficiency.